Navigation Links
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
Date:5/6/2008

en evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Phase 2 Study Details

The Phase 2 study is a two-arm, randomized, controlled 100-patient trial of first-line treatment of metastatic CRC. The objective of the Phase 2 trial is to compare the safety and efficacy of intravenous picoplatin given once every four weeks in the FOLPI regimen with oxaliplatin in combination with 5- fluorouracil and leucovorin in the modified FOLFOX-6 regimen and to evaluate clinical activity. Poniard expects to generate proof-of-concept data from the Phase 2 trial demonstrating that picoplatin has an improved safety profile. This trial could position picoplatin as the preferred platinum agent for the first-line treatment of metastatic colorectal cancer and could potentially enable a Phase 3 study.

-- Poniard initiated the Phase 2 trial in November 2007 based on clinical

activity and promising safety data observed in its 50-patient, Phase 1

dose-escalation study of picoplatin in the FOLPI regimen as a

first-line treatment for metastatic CRC. Results of the Phase 1 trial

were presented at the ASCO Gastrointestinal Cancers Satellite Symposium

in January and demonstrated that picoplatin has a manageable toxicity

in combination with 5-fluorouracil and leucovorin Picoplatin did not

cause severe neurotoxicity (Grade 3 or higher), as is commonly seen in

metastatic CRC patients treated with oxaliplatin as part of the FOLFOX

regimen. Current National Comprehensive Cancer Network (NCCN) Clinical

Practice Guidelines in Oncology for colon cancer encourage the

discontinuation of FOLFOX after three months of therapy or sooner if

significant neurotoxicity develops (Grade
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
5. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2
... ORANGE, Calif., March 16, 2011 To ... beautiful smiles for their patients, leading orthodontic appliance innovator ... Ormco Loyalty Rewards program. Designed to ... selection of orthodontic appliances to treat their patients, the ...
... U L URUI nc. (NYSE Amex: ... an abbreviated 510(k) application with the U.S. Food and Drug ... and mitigation of pain. The principal data supporting ... to Acquacel® Ag in skin graft donor sites. This amended ...
Cached Medicine Technology:Ormco Launches New Loyalty Rewards Program 2Ormco Launches New Loyalty Rewards Program 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... cigarettes in plain packages doesn,t increase the use of ... small stores, according to new research from Australia. ... it tried to prevent Australia from becoming the first ... tobacco products in 2012. Similar legislation is being considered ... surveyed nearly 2,000 adult smokers in Australia before and ...
Breaking Medicine News(10 mins):Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2
... New findings from the St. Jude Children,s Research Hospital ... helped identify the mechanism that makes the childhood eye ... tumor develops so rapidly while other cancers can take ... also led investigators to a new treatment target and ...
... launched a freely available website for published research results ... University Pediatric Cancer Genome Project (PCGP). The PCGP is ... entire genomes of both normal and cancer cells from ... identify genetic mistakes that lead to childhood cancers. ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
... 11 (HealthDay News) -- Keeping an eye on Internet search ... an early warning system about potential surges in seasonal flu ... more effective than waiting for outdated government flu case reports, ... reviewed Google Flu Trends data for Baltimore and matched that ...
... laboratory tests of an imaging agent that shows promise for ... brain signs that now can,t confirm a diagnosis until ... ACS Medicinal Chemistry Letters . Masahiro Ono and ... now exists for AD, which is claiming an increasingly heavy ...
... to condescendingly, excluded from a meeting, or ignored by a ... differently depending on whether your co-worker is a man or ... incivility towards colleagues feel negative emotions especially when the ... work, by Kathi Miner from Texas A&M University and Angela ...
Cached Medicine News:Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 2Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 3Health News:St. Jude Children's Research Hospital launches data website for genome project 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2Health News:Internet Flu Searches May Warn of Outbreaks 2Health News:'I feel your pain ...' 2
... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
Medicine Products: